Immunotherapy
Advanced development and GMP manufacturing solutions for CAR-T, TCR-T, NK, and engineered immune cell therapies.
Autologous & Allogeneic Manufacturing
Supporting autologous and allogeneic programs through process development, analytical characterization, clinical manufacturing, and scale-up.
- Closed, reproducible, consistent and GMP-ready processes
- Integrated process development and MSAT teams, enabling seamless technology transfer
- Multiple technology platforms
- A modular approach that allows for technology-agnostic, custom solutions
- Qualified assays for immunotherapies to quantify potency, purity, identity and viability
Autologous Cell Therapy
- Patient-specific manufacturing
- Vein-to-vein workflow support
- Closed automated production
- Scheduling and chain of identity controls
Allogeneic Cell Therapy
- Master cell banking integration
- Large-batch manufacturing
- Scale-out strategies
- Process consistency across lots
GMP Batches Released
0
Batch Success
0
%
Sterility Failures
100
Years Experience
0
+
Automated & Closed Manufacturing Systems
CliniMACS Prodigy®
- Automated cell selection
- Activation
- Transduction
- Expansion
- Harvest
G-Rex® Bioreactors
- High-density cell expansion
- Scalable manufacturing workflows
Additional Technology Platforms
- Cell processing systems
- Closed fluid management
- Cryopreservation technologies
- Fill-finish integration
Immunotherapy Platform Capabilities Workflow
Manufacturing Sophisticated Solutions in Immunotherapy
OmniaBio is uniquely equipped to pioneer sophisticated solutions to complex and nuanced manufacturing challenges for cellular immunotherapies. We leverage both in-house expertise and key partnerships to solve technical bottlenecks. With our integrated platforms tailored to improve productivity and overcome the hurdles in immune cell proliferation and function, we are positioned to be your partner in delivering both autologous and allogeneic engineered cell therapies.
Process Development Expertise
Process Optimization
- Activation strategies
- Transduction enhancement
- Expansion optimization
- Yield improvement
Platform Transfer
- Internal process transfer
- Client-developed process qualification
- Manufacturing readiness assessments
Scalability Assessments
- Bench-to-clinic translation
- Cost-of-goods optimization
- Process robustness studies
Manufacturing Sophisticated Solutions in Immunotherapy
Cell Characterization
- Flow cytometry
- Immunophenotyping
- Cell population analysis
Potency Testing
- Cytotoxicity assays
- Functional characterization
- Cytokine analysis
Product Release
- Identity
- Purity
- Viability
- Sterility
- Residual testing
Method Development & Qualification
- Custom assay development
- Assay transfer
- Qualification support
Same day services to anywhere in North America*
Efficient and secure transportation with flexible scheduling
*Lower 48th U.S. states and southern Canadian provinces
210 miles
To DTW
85 miles
To BUF
10 miles
To YHM
40 miles
To YYZ
Inbound: under 22 hours
Outbound: under 18 hours
Outbound: under 18 hours
Same Day Services to Anywhere in North America*
Efficient and Secure Transporation with Flexible Scheduling
*Lower 48th U.S. states and southern Canadian provinces
210 Miles /
338 Kilometers
To DTW
To DTW
40 Miles /
64 Kilometers
To YYZ
To YYZ
85 Miles /
137 Kilometers
To BUF
To BUF
10 Miles /
16 Kilometers
To YHM
To YHM
Inbound: Under 22 hours
Outbound: Under 18 hours
Outbound: Under 18 hours
Case Studies & Technical Data
Our Expertise on Demand
Related Thought Leadership & Resources
Technical Poster
This technical poster shares data demonstrating one of our closed, automated CAR-T manufacturing platforms that can be tailored to accommodate specific client needs.
Blog
By addressing challenges related to cost, production efficiency, and patient safety, allogeneic CAR-T cell therapies have the potential to make CAR-T cell therapies more accessible and consistent.
Technical Poster
This technical poster shares data demonstrating our comprehensive analytics, which is essential to any cell therapy candidate.
Partnership pairs GMP-manufactured iPSC lines with matched RUO equivalents, giving developers well-characterized, donor-eligible starting materials from early research through clinical development. Supporting comparability data for the RUO and GMP lines to be presented at the 2026...
TORONTO, CANADA & DUBLIN IRELAND — June 15th, 2026 — CCRM and its CDMO subsidiary OmniaBio Inc., today announced an agreement with Avectas Limited (“Avectas”) to evaluate its automated, integrated and scalable cell therapy manufacturing...
HAMILTON & TORONTO ONTARIO – December 23, 2025 – OmniaBio Inc., Canada’s largest cell and gene therapy (CGT) contract development and manufacturing organization (CDMO), today announced that Health Canada has awarded the company a Drug Establishment License...